Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children, Active Treatment Arm Open-Label Extension Study (RAMSES OLE)

Trial Profile

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children, Active Treatment Arm Open-Label Extension Study (RAMSES OLE)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2018

At a glance

  • Drugs AR 101 (Primary)
  • Indications Peanut hypersensitivity
  • Focus Adverse reactions; Registrational
  • Acronyms RAMSES OLE
  • Sponsors Aimmune Therapeutics
  • Most Recent Events

    • 26 Mar 2018 Planned number of patients changed from 300 to 330.
    • 26 Mar 2018 Planned End Date changed from 1 Jul 2018 to 1 Apr 2019.
    • 26 Mar 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top